Suppr超能文献

[关于使用钙拮抗剂治疗冠心病和高血压的争议]

[Controversy about using calcium antagonists for treatment of coronary disease and hypertension].

作者信息

Głuszek J, Pawlaczyk-Gabriel K

机构信息

Kliniki Nadciśnienia Tetniczego Instytutu Kardiologii Akademii Medycznej w Poznaniu.

出版信息

Przegl Lek. 1997;54(9):597-601.

PMID:9501678
Abstract

Calcium antagonists are widely used in therapy of hypertension and angina pectoris. Their advantage is good efficacy, relatively few and not dangerous side effects and first of all lack of bad metabolic effects (hypokalemia, hyperuricemia, hyperinsulinemia and hyperlipoproteinemia). In contrast to beta-blockers and diuretics, which decline mortality from myocardial infarctions and strokes there are not similar information concerning calcium antagonists. Two meta-analysis from 1995 unexpectedly suggest, that some preparations of calcium antagonists increase mortality from myocardial infarctions and strokes. In our paper we discuss possible pathogenetic (harmful) mechanisms, pay attention to each class of calcium antagonists and time of action of the particular drugs. Short acting nifedipine formulation should be withdrawn from chronic hypertension and angina pectoris therapy. Ongoing multicenter trials in several European countries and in USA will decide the usefulness of other calcium antagonists preparations.

摘要

钙拮抗剂广泛应用于高血压和心绞痛的治疗。它们的优点是疗效良好、副作用相对较少且不危险,首先是没有不良代谢影响(低钾血症、高尿酸血症、高胰岛素血症和高脂蛋白血症)。与能降低心肌梗死和中风死亡率的β受体阻滞剂和利尿剂不同,关于钙拮抗剂没有类似的信息。1995年的两项荟萃分析意外地表明,某些钙拮抗剂制剂会增加心肌梗死和中风的死亡率。在我们的论文中,我们讨论了可能的致病(有害)机制,关注了每一类钙拮抗剂以及特定药物的作用时间。短效硝苯地平制剂应退出慢性高血压和心绞痛的治疗。目前在欧洲几个国家和美国正在进行的多中心试验将决定其他钙拮抗剂制剂的有效性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验